Therapeutic efficacy resulting from combining Trastuzumab and Pertuzumab in the treatment of Her2 overexpressing breast cancer patients has been shown to increase patient survival. This is thought to arise from inhibition of receptor dimerization and the immune tagging of the cancer cells; however, the underlying molecular mechanisms have remained enigmatic. Previously, a molecular modeling study suggested that this resulted from colocalization of the two antibodies on to the extracellular domain of Her2. We report here the experimental characterization of this interaction by measuring the binding kinetics of these two whole antibodies and their F(ab)s to the extracellular domain of Her2 in solution. We found that both antibodies (the whole antibodies and the fragments) colocalized on to Her2, but did not augment the binding of each other.
Therapeutic efficacy resulting from combining drugs in oncology is increasingly being reported. A significant improvement in survival was recently reported in the treatment of Her2 overexpressing breast cancer patients from combining the antibodies Trastuzumab and Pertuzumab.1 However, the underlying molecular mechanisms have remained enigmatic. A hypothesis was put forward from a molecular modeling study that suggested a partial rationale in the form of enhanced affinities arising from colocalization of the two antibodies on to the extracellular domain of Her2.2 We report here the experimental characterization of this interaction by measuring the binding kinetics (using the BLItz biosensor system, ForteBio, Pall, Singapore) of these two antibodies (whole antibodies and F(ab)s; see Figure 1) to the extracellular domain of Her2 in solution.
Briefly, 25 μg/ml of HIS-tagged Her2 (cat no: 10004-H08H, Sino Biologicals, China) was bound onto Nickel-nitrilotriacetic acid (Ni-NTA) biosensors (ForteBio, Pall). Trastuzumab (Roche, Singapore) and Pertuzumab (Roche) to Her2 binding kinetics were measured using the BLI technology from ForteBio (http://www.fortebio.com/bli-technology.html). Whole antibody-Her2 interactions were calculated from five serial 1:2 dilutions. Synergistic binding of the whole antibodies and F(ab)s were measured from successive loading of the antibodies. Human IgG control (cat no: PN 18-1073, lot no: 3060036, ForteBio, Pall) was used as the control IgG. The F(ab)s of both Trastuzumab and Pertuzumab were prepared by papain digestion using the Pierce™ Fab Preparation Kit (cat no: 44985, Life Technologies, Singapore).
Our measurements found the kinetics of whole Trastuzumab to be comparable to previous surface plasmon resonance measurements.3 We see that Trastuzumab (in both its IgG and F(ab) states) (see Figure 1a,b,f, respectively) binds tighter than the corresponding Pertuzumab states, an observation in support of the earlier computational model based on the F(ab) states.2 Preloading of Her2 with saturating (200 nM) and non-saturating (50 nM) concentrations of each antibody (shown in plateau sections of Figure 1c–e) followed by measurements of the second antibody appears to have little effect on the binding of the latter. An observation to note is that the presence of the control IgG does seem to increase the Kd of both antibodies (compare Figure 1a, c and Figure 1b, d) thus making comparisons with binding of antibodies alone, a little complex.
We repeated the experiments to rule out confounding variables under the following conditions: (1) using only Trastuzumab and Pertuzumab F(ab)s (Figure 1g, h); (2) preloading Her2 with F(ab) or whole antibody, followed by measurement of the alternative antibody as a whole or F(ab), respectively (not shown); (3) preloading the alternative antibody overnight (performed for both F(ab)s and whole antibodies, data not shown). Under these conditions, minimal binding changes of either antibody were observed. This suggests that the state of the antibodies (F(ab)s or whole Igs, or mixed) were not contributing factors nor was the time of incubation a factor in inducing synergistic binding.
We have demonstrated, in agreement with the computational modeling, that Tratsuzumab binds to the extracellular domain of Her2 with a higher affinity than does Pertuzumab. We have also shown, in agreement with the modeling, that both antibodies can colocalize onto the extracellular domain of Her2. However, in contrast to the modeling, we did not observe significant synergistic binding effects through prior Trastuzumab or Pertuzumab loading (note that only the extracellular portion of Her2 was used in our experiments). The discrepancy between these findings and the hypotheses generated from the modelling2 may arise from the fact that the modeling may not have captured the complex nature of the interactions which, owing to the much larger system size of the ternary complexes of Her2–Trastuzumab–Pertuzumab, would likely require longer simulation times than that have been used. However, the complex nature of these interactions and the vast differences between in silico, in vitro, and in vivo measurements4,5 rule out any unambiguous conclusions. Nevertheless, the simple fact that both antibodies can bind simultaneously and without significant interference, may be sufficient to further impede Her2 dimerization and enforce the engagement of downstream immune effectors to explain the clinical observations.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109–119.
Fuentes G, Scaltriti M, Baselga J, Verma CS . Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res 2011; 13: R54.
Karagiannis P, Singer J, Hunt J, Gan SKE, Rudman SM, Mechtcheriakova D et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother 2009; 58: 915–930.
Cass RM, Anderson BR . The disappearance rate of skin sensitizing antibody activity after intradermal administration. J Allergy 1968; 42: 29–35.
Wan T, Beavil RL, Fabiane SM, Beavil AJ, Sohi MK, Keown M et al. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat Immunol 2002; 3: 681–686.
This work was supported by JCO1334i00050 from the Joint Council Office, Agency for Science, Technology, and Research, Singapore.
The authors declare no conflict of interest.
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Lua, WH., Gan, SE., Lane, D. et al. A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2. npj Breast Cancer 1, 15012 (2015). https://doi.org/10.1038/npjbcancer.2015.12
This article is cited by
Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
Breast Cancer Research and Treatment (2022)
The biological activity of bispecific trastuzumab/pertuzumab plant biosimilars may be drastically boosted by disulfiram increasing formaldehyde accumulation in cancer cells
Scientific Reports (2019)
The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding
Scientific Reports (2018)
Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability
Journal of Pharmacokinetics and Pharmacodynamics (2017)
Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer
European Journal of Nuclear Medicine and Molecular Imaging (2017)